November 25, 2016 - By Ruchi Gupta · 0 Comments
The stock of Biodel Incorporated (NASDAQ:BIOD) registered an increase of 6.42% in short interest. BIOD’s total short interest was 102,800 shares in November as published by FINRA. Its up 6.42% from 96,600 shares, reported previously. With 1.21 million shares average volume, it will take short sellers 0 days to cover their BIOD’s short positions. The stock closed at $19.46 during the last session. It is down 80.56% since April 4, 2016 and is uptrending. It has outperformed by 75.15% the S&P500.
Albireo Pharma, Inc., formerly Biodel Inc., is a clinical-stage biopharmaceutical company. The company has a market cap of $1.25 billion. The Firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. It currently has negative earnings. The Company’s clinical pipeline includes over two Phase II product candidates and one Phase III product candidate.
Insitutional Activity: The institutional sentiment decreased to 0.5 in Q2 2016. Its down 0.14, from 0.64 in 2016Q1. The ratio dived, as 6 funds sold all Albireo Pharma Inc shares owned while 5 reduced positions. 1 funds bought stakes while 6 increased positions. They now own 5.68 million shares or 19.38% less from 7.05 million shares in 2016Q1.
Acadian Asset Management Limited Liability Company has invested 0% of its portfolio in Albireo Pharma Inc (NASDAQ:BIOD). Kcg Holdings Incorporated last reported 68,782 shares in the company. Blackrock Fund Advsrs, a California-based fund reported 11,195 shares. Ladenburg Thalmann Fincl Serv Inc last reported 0% of its portfolio in the stock. The Minnesota-based Ameriprise Financial has invested 0% in Albireo Pharma Inc (NASDAQ:BIOD). Deutsche Natl Bank Ag last reported 0% of its portfolio in the stock. Citadel Advisors Ltd Com has 74,155 shares for 0% of their US portfolio. National Bank & Trust Of America De last reported 0% of its portfolio in the stock. Susquehanna Intl Gru Llp holds 0% or 11,166 shares in its portfolio. Finemark State Bank And Trust, a Florida-based fund reported 7,302 shares. California Employees Retirement Sys has invested 0% of its portfolio in Albireo Pharma Inc (NASDAQ:BIOD). Northern Tru Corporation last reported 45,764 shares in the company. Moreover, Psagot Inv House has 0% invested in Albireo Pharma Inc (NASDAQ:BIOD) for 71,000 shares. Creative Planning has 150 shares for 0% of their US portfolio. Plante Moran Finance Ltd Liability has 0% invested in the company for 1,470 shares.
Out of 2 analysts covering Biodel (NASDAQ:BIOD), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. Biodel has been the topic of 2 analyst reports since December 18, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Ladenburg Thalmann given on Friday, December 18. William Blair downgraded Albireo Pharma Inc (NASDAQ:BIOD) on Friday, December 18 to “Market Perform” rating.
More recent Albireo Pharma Inc (NASDAQ:BIOD) news were published by: Quotes.Wsj.com which released: “News Albireo Pharma Inc.ALBO” on November 03, 2016. Also Streetinsider.com published the news titled: “Form 3 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Sermon Charles” on November 07, 2016. Marketwired.com‘s news article titled: “Biodel Inc. and Albireo Limited Agree to Combine” with publication date: May 25, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta